Effects of Weight Status and Related Metabolic Disorders on Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrial Cancer: A Retrospective Study.

BACKGROUND

Although obesity was an independent risk factor for fertility-sparing treatment in endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC), the roles of other weight statuses and related metabolism were unclear. This study aimed to investigate the body mass index (BMI) interval that produced optimal treatment efficacy and the effects of related metabolic disorders in EAH/EEC patients.

METHODS

A total of 286 patients (including 209 EAH and 77 well-differentiated EEC) under progestin therapy were retrospectively analyzed. The cumulative complete response (CR) rate, relapse rate, and fertility outcomes were compared among different weight or metabolic statuses.

RESULTS

Underweight and overweight/obese status significantly decreased the cumulative 16-week and 32-week CR rate ( = 0.004, = 0.022, respectively). The highest 16-week CR rate was observed at a BMI of 21-22 kg/m in the overall population ( = 0.033). Obesity (HR 0.37, 95%CI 0.15-0.90, = 0.029) and PCOS (HR 0.55, 95%CI 0.31-0.99, = 0.047) were associated with lower 16-week CR rate. Hyperuricemia (HR 0.66, 95%CI 0.45-0.99, = 0.043) was associated with lower 32-week CR rate. The 16-week and 32-week CR rate ( = 0.036, = 0.008, respectively) were significantly lower in patients exhibiting both obesity and hyperuricemia.

CONCLUSIONS

The optimal fertility-sparing treatment efficacy was observed at a BMI of 21-22 kg/m in EAH/EEC. Hyperuricemia was an independent risk factor for long-term treatment outcomes.